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Abstract
Background: Pregnancies induced by in vitro fertilisation (IVF) often result in twin gestations, which are associated
with both maternal and perinatal complications. An effective way to reduce the number of IVF twin pregnancies is
to decrease the number of embryos transferred from two to one. The interpretation of current studies is limited
because they used live birth as outcome measure and because they applied limited time horizons. So far, research
on long-term outcomes of IVF twins and singletons is scarce and inconclusive. The objective of this study is to
investigate the short (1-year) and long-term (5 and 18-year) costs and health outcomes of IVF singleton and twin
children and to consider these in estimating the cost-effectiveness of single embryo transfer compared with
double embryo transfer, from a societal and a healthcare perspective.
Methods/Design: A multi-centre cohort study will be performed, in which IVF singletons and IVF twin children
born between 2003 and 2005 of whom parents received IVF treatment in one of the five participating Dutch IVF
centres, will be compared. Data collection will focus on children at risk of health problems and children in whom
health problems actually occurred. First year of life data will be collected in approximately 1,278 children (619
singletons and 659 twin children). Data up to the fifth year of life will be collected in approximately 488 children
(200 singletons and 288 twin children). Outcome measures are health status, health-related quality of life and costs.
Data will be obtained from hospital information systems, a parent questionnaire and existing registries.
Furthermore, a prognostic model will be developed that reflects the short and long-term costs and health
outcomes of IVF singleton and twin children. This model will be linked to a Markov model of the short-term cost-
effectiveness of single embryo transfer strategies versus double embryo transfer strategies to enable the calculation
of the long-term cost-effectiveness.
Discussion: This is, to our knowledge, the first study that investigates the long-term costs and health outcomes of
IVF singleton and twin children and the long-term cost-effectiveness of single embryo transfer strategies versus
double embryo transfer strategies.
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In the Netherlands, about 16,000 IVF treatments are
performed every year [1]. As a result, approximately
2.3% of all Dutch children are born from a pregnancy
established by in vitro fertilization (IVF) [2]. A common
complication of IVF is multiple pregnancy [3], which
occurs in 20-25% of all IVF pregnancies [4-7]. Obstetri-
cians and neonatologists express a preference to prevent
twin pregnancies in IVF because of maternal and perina-
tal complications [7]. Pregnancy-induced maternal com-
plications occur three to seven times more often in
multiple than in singletons pregnancies [8]. The most
common maternal complications of a twin pregnancy
are pregnancy-induced hypertension, pre-eclampsia,
anaemia, antepartum and postpartum haemorrhage,
uterine atony and dystocia, increased operative delivery,
uterine rupture and preterm labour [8,9]. It is well
known that twin status is associated with perinatal com-
plications. Perinatal morbidity and mortality is increased
four-to ten-fold in twins [8]. Twins are born prema-
turely more often than singletons. Approximately 50%
of twin deliveries occur before 37 weeks gestation
[10-12], and this is considered to be the factor that is
largely responsible for the excess of perinatal and neo-
natal deaths and neonatal morbidity in twins [11,13,14].
Twins also have a lower birth weight compared to sin-
g l e t o n s[ 9 , 1 5 , 1 6 ] ,e v e nw h e nb o r nf u l lt e r m[ 1 7 ] .
Because of the high frequency of complications, the
average twin pregnancy requires more medical care than
a singleton pregnancy, resulting in higher costs. Results
from the Dutch TWIN study indicated that hospital
costs of children born from IVF up to one year follow-
ing birth add up to about €3,000 for singletons and
€9,000 for twin children [18].
The explanation for the increased risk of a multiple
pregnancy after IVF is the policy of transferring two
embryos into the uterus (double embryo transfer; DET)
[19], which is still customary in the majority of women
receiving IVF treatment, particularly in older women. A
successful way to reduce the number of twin pregnan-
cies after IVF is to transfer only one embryo (single
embryo transfer; SET) [20-26]. The current policy in
The Netherlands is to offer SET in good prognosis
patients (i.e. young patients with good quality embryos).
The decision for the number of embryos to transfer -
either one or two embryos - is established by both the
couple and professionals [27].
Several short-term (cost-) effectiveness studies have
shown that transferring one fresh embryo and then, if
needed, one frozen-and-thawed embryo dramatically
reduces the number of twin pregnancies while achieving
similar cumulative pregnancy rates to transferring two
embryos in good prognosis patients [20,21,23-26,28-30]. A
review by Fiddelers et al. [31] of economic evaluations of
SET versus DET concluded that, from a cost-effectiveness
point of view, SET is only preferred in good prognosis
patients and when frozen-and-thawed cycles are included.
The conclusions of the review are confirmed by a detailed
(cost-)effectiveness analysis [20,26] and a Markov cost-
effectiveness model [32]. The Markov model compared
seven embryo transfer strategies varying from three cycles
SET to three cycles DET and several combination strate-
gies. From the Markov-chain based study, it was con-
cluded that DET is more effective but also more costly
compared to SET, with an Incremental Cost-Effectiveness
Ratio (ICER) around €20,000 for an extra live birth.
Interpretation of current cost-effectiveness studies
comparing SET strategies with DET strategies is compli-
cated. First, live birth is frequently used as outcome mea-
sure. To reflect the fact that twin pregnancies and twin
births carry a higher risk for complications than singleton
pregnancies and singleton births, both singleton and twin
births are counted as one unit of live birth. However,
based on results of preference studies, counting a twin
birth as one live birth is incorrect from a subfertile cou-
ples’ point of view [33-39]. Furthermore, a live birth is an
intermediate outcome as long-term consequences are not
included. Besides, it is not a preference-based outcome
measure as opposed to Quality Adjusted Life Years
(QALYs), which is a commonly used outcome measure
in economic evaluations. Second, published cost-effec-
tiveness analyses applied a limited time horizon, up to six
months after delivery. If a child experiences permanent
morbidity the consequences are lifelong, and thus data
on long-term costs and outcomes associated with single-
tons and twins born after IVF should be included in the
analysis in order to obtain a valid estimate of the incre-
mental cost-effectiveness of different embryo transfer
strategies. Third, most parents prefer a complete family.
This implies that cost-effectiveness studies should prefer-
ably include the first IVF treatment as well as subsequent
attempts for a second child. Fourth, even with current
data, a societal preference statement on the choice
between SET and DET depends on the amount of money
society is prepared to pay for one extra live birth (ceiling
ratio) [31]. No agreement exists on an appropriate ceiling
ratio for one extra live birth, as opposed to the ceiling
ratio for a QALY [1,40]. The right to procreate is gener-
ally regarded as fundamental, and from this principle one
would expect a high ceiling ratio.
The proposed study - the TwinSing study - will inves-
tigate the short (1-year) and long-term (5 and 18-year)
costs, health outcomes and health-related quality of life
( H R Q o L )o ft w i n sa n ds i n g l e t o n sb o r nf r o mI V Ff o r
broad use in cost-effectiveness analyses comparing SET
strategies with DET strategies.
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Most studies on the long-term follow up of IVF children
so far did not compare IVF twin children with IVF sin-
gletons, but compared children born from IVF with
naturally conceived children [41-45].
Long-term health-related outcomes
Up till now only few studies have actually compared
long-term health-related outcomes of IVF twins and IVF
singletons [46-48]. They reported varying results regard-
ing physical health and developmental outcomes. Pin-
borg et al. [48] reported that twins between two and
seven years of age have a similar risk of neurological
sequelae and cerebral palsy compared to singletons of
the same age. In another study, Pinborg et al. [47]
observed no discrepancies between IVF twins and IVF
singletons aged three to four years regarding severe neu-
rological disabilities, allergic disorders, common infec-
tions and motor function. Nevertheless, IVF twins had
poorer speech development and poorer general health
status. Mortality rates did not differ significantly
between IVF twins and IVF singletons, although there
was a tendency towards a higher mortality rate in IVF
twins. Bonduelle et al. [46] reported that the occurrence
of malformations was not statistically different between
IVF twins and singletons, whereas the developmental
outcomes of IVF twins, as measured with the Bayley
instrument, were significantly worse compared to IVF
singletons at the age of two years.
Other studies compared both IVF singletons with
naturally conceived singletons and IVF twins with natu-
rally conceived twins [42-45]. Although these studies
provided figures about the long-term health status of
IVF twins and IVF singletons, no statistics were pre-
sented and no conclusions were drawn regarding the
comparison between IVF twins and IVF singletons. All
three studies suggested that the health of IVF twins was
worse than that of IVF singletons. Klemetti et al. [43]
showed that the risks for cerebral palsy, behavioural dis-
orders, asthma, pneumonia and diarrhoea were higher
for IVF twins aged two years compared with IVF single-
tons of the same age. Koivurova et al. [44] reported that
six out of eight diseases were more prevalent in IVF
twins than in IVF singletons, i.e. respiratory diseases,
pneumonia, obstructive bronchitis, asthma, juvenile
arthritis and neurological signs. Another study of Koi-
vurova et al. [42] showed that risks of having diagnoses
related to diseases affecting the central nervous system
were higher for IVF twins. Furthermore, the proportion
of children with low weight, low height and inability to
perform at least one developmental test was higher in
the IVF twin group compared to singletons for several
age categories up to three years. Strömberg et al. [45]
found a higher proportion of neurological sequelae in
IVF twins compared to IVF singletons aged 18 months
to 14 years. Overall, the results of these studies are
ambivalent, some hinting at worse outcomes for IVF
twins and some showing similar outcomes for IVF twins
and singletons.
Long-term costs
At this moment only a few cost studies have been per-
formed [41-43,47,49]. Most studies were restricted to an
evaluation of the use of hospital resources. Two studies
statistically compared long-term resource use and/or
c o s t so fI V Ft w i n sa n dI V Fs i n g l e t o n s[ 4 7 , 4 9 ] .As t u d y
by Pinborg et al. [47] revealed no difference in the risk
of hospitalization and the number of hospitalizations
per child between IVF twins and IVF singletons aged
three to four years. In contrast, they showed in another
study that IVF twins aged two to seven years were
more likely to be admitted to a hospital, had more
admissions per child, longer hospital stays, as well as
more surgical interventions and special needs [49]. Even
t e r mt w i n sw e r em o r el i k e l yt ob eh o s p i t a l i z e dt h a n
term singletons [49].
Other studies did not statistically confirm differences
in resource use or costs of IVF twins and IVF singletons
[41-43]. Koivurova et al. [42] concluded that the costs of
post-neonatal care were almost equal for IVF twins and
IVF singletons during a seven-year follow-up period. A
large registry study by Ericson et al. [41] with an average
follow-up of six years showed that IVF twins had about
twice as much hospital days as IVF singletons. Klemetti
et al. [43] also reported more resource use by IVF twins
up to two to four years of age. Medication use was mea-
sured up to two years of age, whereas the use of hospital
services was measured up to four years of age. More IVF
twins than IVF singletons had long-term medication use,
were hospitalised, and had longer hospital stays. Overall,
the majority of these studies reported higher use of
resources for IVF twins. It has been estimated that life-
time extra health care costs of a twin pregnancy add up
to €30,000 in the Netherlands [50].
Long-term impact on parent’s life
Mothers of two to five year old IVF twins experienced
significantly higher levels of parenting stress and depres-
sion than mothers of IVF singletons and were less likely
to obtain pleasure from their child and to be in paid
employment [13,51].
Conclusion
Overall the current evidence confirms that post-neonatal
costs are higher in IVF twins compared to IVF single-
tons. Reported results regarding health outcomes are
inconclusive. Some studies were, however, not designed
to detect significant differences between IVF twins and
IVF singletons and probably lacked statistical power to
detect differences. The available evidence is insufficient
to estimate the long-term cost-effectiveness of SET stra-
tegies compared with DET strategies.
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In the Netherlands, long-term results from IVF children
are currently lacking. It is timely to obtain an objective
estimate of the long-term costs and health outcomes of
twins and singletons born from IVF, to support the
claim that twin pregnancies are a complication of IVF
that should be prevented. Objective here means empiri-
cally based and taking account for sources of bias. To
support the general believe that twin pregnancies are a
complication of IVF and to make an evidence-based
decision on the preferred embryo transfer strategy in
IVF, both long-term costs and health outcomes of twins
and singletons need to be estimated.
The TwinSing study is funded by the Netherlands
Organisation for Health Research and Development
(ZonMW), grant number 80-82310-98-09094. The study
is approved by the Institutional Ethical Board of the
Maastricht University Medical Centre (Ref no: 09-4-019)
and the study is actively supported by the Dutch patient
association Freya. The Ethical Board of the Maastricht
University Medical Centre judged that the TwinSing
study is not subject to the Medical Research Involving
Human Subjects Act (WMO).
Objective and research questions
The objective of the TwinSing study is to investigate the
short (1-year) and long-term (5 and 18-year) costs,
health outcomes and HRQoL of twins and singletons
born from IVF. These results will be linked to a Markov
model in which seven embryo transfer strategies are
c o m p a r e d[ 3 2 ] ,t oe n a b l ee s t i m a t i o no ft h el o n g - t e r m
cost-effectiveness of SET strategies versus DET
strategies.
The research questions are:
1. What are the short (1-year) and long-term (5 and
18-year) health outcomes of IVF twins and
singletons?
2. What are the short (1-year) and long-term (5 and
18-year) costs of IVF twins and singletons?
3. What is the short (1-year) and long-term (5 and
18-year) cost-effectiveness of SET strategies versus
DET strategies from a societal and healthcare
perspective?
4. What is the value of additional information
through research to reduce decision uncertainty?
Methods/Design
Design
A retrospective multi-centre (n = 5) cohort study will be
performed, in which a representative sample of IVF twin
children will be compared with a representative sample
of IVF singletons with respect to mortality, health
outcomes, HRQoL and costs from birth up to five years
of life. Subsequently, future costs and health outcomes
up to 18 years of life will be modelled. Input for the
model will be based on the empirically collected data up
to five years of life, existing databases, literature and
expert opinion.
Participants
The study population consists of twins and singletons
born from IVF between 2003 and 2005, of whom par-
ents have received IVF treatment in one of the five par-
ticipating IVF centres in the Netherlands (Academic
Medical Centre, Maastricht University Medical Centre,
Radboud University Nijmegen Medical Centre, Erasmus
Medical Centre and University Medical Center Utrecht).
In the Netherlands, subfertility care is well-organized
and centred in thirteen licensed clinics [52]. Hospitals
without a licence can initiate and monitor the stimula-
tion phase and refer to a licensed hospital for both
oocyte retrieval and embryo transfer (satellite clinics) or
for embryo transfer alone (transport clinics). Five of the
13 licensed centres and their collaborating transport-
and satellite clinics, participate in the TwinSing study.
The full sample consists of all IVF twins and IVF sin-
gletons born between 2003 and 2005 of whom parents
have received treatment in one of the participating cen-
tres. A total of 4,809 ongoing pregnancies were reported
by these IVF centres between 2003 and 2005, of which -
3,789 singleton and 1,020 twin pregnancies. The actual
size of the full sample will be somewhat lower since the
reported figures are indicative; they are based on
ongoing pregnancies not live births. Inclusion of an
older cohort of IVF children is not considered to be
valid, since the quality and results of IVF, neonatal and
paediatric care have improved considerably during the
last decade and since this study relies heavily on retro-
spective data collection, both from existing registries as
well as from parents.
Data collection will primarily focus on the subgroup of
children ‘at risk’ for health problems and on those chil-
dren in which health problems have actually occurred.
Therefore, for all children included in the full sample,
information from the Perinatal Registry Netherlands
(PRN) will be studied. Based on information from the
PRN and the establishment of a clear set of criteria, all
children at ‘high risk’ and a random sample of children
at ‘low risk’ will be selected. All singleton children at
‘moderate risk’ and a random sample of twin children at
‘moderate risk’ will also be selected (see figure 1).
Together, these children will form the basis for empiri-
cal data collection with respect to the first year of life,
and will further be referred to as the base sample. Based
on results up to the first year of life, the base sample of
children will further be reduced for detailed data
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the children up to five years of life and data estimation
up to 18 years of life (further referred to as the reduced
sample). Infant will be the unit of analysis. The selection
of IVF twin children of a pair for inclusion in the base
sample and reduced sample will occur independently.
In order to sufficiently take account of heterogeneity
within the children who experienced health problems, it
is expected that costs and outcome data of at least 100
singletons and 100 twin children with health problems
are required in the reduced sample. Regarding children
without health problems, data of 50 singletons and 50
twin children is expected to be sufficient, as variance
will be considerably lower. Taking sufficiently account
of missing data in all phases of data collection (5% for
risk stratification, 10% for data collection up to one year
of life and 20% for data collection up to five years of
life), a sample size of 175 twin children with health pro-
blems, 56 twin children without health problems, 104
singletons with health problems, and 56 singletons with-
out health problems, is required for the reduced sample.
Data collection
Data collection full sample
The five participating IVF centres will each provide a
dataset consisting of mothers who have had an effective
IVF treatment and gave birth to a singleton or twin
between 2003 and 2005. The data received from the IVF
centres will be linked to the PRN database, which
encompasses information regarding mother, pregnancy
and newborn. The data will be matched to the PRN
database based on the birth date of the mother, parity
of the mother, (an estimation of) the birth date of the
child(ren), and whether it was a singleton or twin birth.
Risk stratification
Risk stratification will be applied to all children in the
full sample. Based on information from the PRN regard-
ing the pregnancy (weeks gestation) and the newborn
(birth weight, Apgar score and congenital malforma-
tions), the children of the full sample will be assigned to
ar i s kp r o f i l e( i . e .‘low risk’, ‘moderate risk’ or ‘high
risk’). The risk stratification criteria are: 1) prematurity
(< 37 weeks gestation); 2) 5-minute Apgar score (< 7);
3) congenital malformations; and 4) birth weight
(< 2,000 gram) (see figure 1). The criteria are set such
that the probability of a false negative, i.e. the chance
that a child ‘at risk’ is assigned to the low risk category,
is minimized. A child will be assigned to the ‘moderate
risk’ category if the child is born before 37 weeks gesta-
tion, has a Apgar score below seven, or has a congenital
malformation. If the child also has a birth weight below
2,000 gram, the child will be assigned to the ‘high risk’
category. The other children will be assigned to the ‘low
risk’ category. Based on figures reported by the PRN
[12] and expert opinion it is expected that approxi-
mately 8% of the singletons will be assigned to the
‘moderate risk’ or ‘high risk’ category. All ‘moderate risk’
and ‘high risk’ singletons and a random selection of 10%
of the remaining (’low risk’) singletons will be included
in the base sample. Based on figures reported by the
PRN [12] and expert opinion it is expected that half of
the twin children is born before 37 weeks gestation,
have a low APGAR score or a congenital malformation.
Approximately 40% of these twin children will also have
a low birth weight (20% of all twin children) and will be
assigned to the ‘high risk’ category. The other 60% of
these twin children will have a birth weight above 2000
gram (30% of all twin children) and will be assigned to
the ‘moderate risk’ category [12]. All other children
(50% of all twin children) will be assigned to the ‘low
risk’ category. All twin children of the ‘high risk’ cate-
gory, a random selection of 30% of the ‘moderate risk’
category and a random selection of 10% of the ‘low risk’
category will be included in the base sample.
Empirical data collection up to the first year of life
Data with respect to the first year of life will be col-
lected in children of the base sample. Based on figures
reported by the PRN over 2004 [12] and expert opinion
it is expected that approximately 1,278 children will be
included in the base sample. The estimated number of
children in each risk category is shown in figure 1.
Cost and outcome data up to the first year of life will
be obtained from the hospital information systems of
the relevant hospitals, existing registries and, if neces-
sary, patient charts will be reviewed to obtain relevant
cost and outcome data. The following registries will be
used: 1) the PRN, which encompasses information
regarding mother, pregnancy and the newborn; 2) the
National Medical Registration (LMR), which registers
medical and administrative data of all patients who have
been admitted or have received outpatient treatment in
Dutch hospitals; and 3) the Netherlands Twin registry
(NTR), which follows a cohort 72,000 twins regarding
pre- and perinatal information, health status, growth
and motor development and behaviour [53,54]. As we
intend to collect follow up data directly from hospital
records, the use of data from the LMR will be optional.
It is expected that data collection up to the first year of
life will succeed in 90% of these children.
Empirical data collection from the first year of life up to the
fifth year of life
Based on empirical collected costs and outcome data up
to the first year of life, a subgroup of children will be
selected for data collection up to the fifth year of life,
referred to as the reduced sample. All children with
resolved or persistent health problems, and a random
sample of children without resolved or persistent health
problems will be included in the reduced sample.
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resolved and persistent health problems are expected in
4.0% of the singletons and in 12.5% of the twin children.
Approximately 488 children will be included in the
reduced sample (see figure 1). Besides the data sources
mentioned above, cost and outcome data up to the fifth
year of life will also be gathered by means of a parent
questionnaire. The questionnaire will consist of three
parts, the first part referring to the past, the second part
referring to the present and the third part referring to
expectations regarding the future. The parent question-
naire will focus on health outcomes, HRQoL and costs.
Data estimation up to the 18th year of life
Costs and outcome data of the reduced sample up to
the 18
th year of life will be estimated, based on 1)
empirical costs and outcomes up to five years of life; 2)
parent estimations by means of a questionnaire; and 4)
a matched sample (n = 250) of 18-year old twin chil-
dren, of whom NTR data referring to the past will be
studied. The sample from the NTR will be chosen such
that their past health at five years of age matches with
the health status of the children of the reduced sample
who will have an average age of five years. If empirical
data are missing, data will be obtained by means of lit-
erature and/or expert opinion. Based on these data
inputs, a prognostic model - the TwinSing model - will
be developed.
Outcome measures
Outcome measures are:
1. Health outcomes of the singleton and twin chil-
dren, such as (perinatal) mortality, morbidity, perina-
tal outcomes (birth weight, prematurity, APGAR),
malformations, developmental problems (psychomo-
tor, cognitive and growth) and behavioural
outcomes.
2. Health related quality of life of the singleton and
twin children. HRQoL will be measured via proxy
r a t i n g sb y( o n eo f )t h ep a r e n t sb ym e a n so ft h e
EuroQol (EQ-5D) and the Health Utilities Index
(HUI3). The EuroQol provides a simple descriptive
profile, combining scores on mobility, self-care, daily
activities, pain/discomfort and depression/anxiety
into a single index value for health status and a VAS
scale (0-100). Utility scores for the health states will
be calculated by using the UK-tariff [55] and by
using the Dutch EQ-5D tariff [56]. The reliability
and validity of the EQ-5D has been established [57].
The proxy version of the EQ-5D has good construct
validity and convergent validity [58]. The HUI3 will
also be used as some studies have reported problems
regarding speech development and cognitive pro-
blems. The HUI3 is a generic measure consisting of
eight attributes (vision, hearing, speech, ambulation,
dexterity, emotion, cognition and pain). Each attri-
bute has five or six levels and 972,000 possible
health states can be defined. The HUI3 has a multi-
plicative scoring function which was derived from
the Standard Gamble (SG) and Visual Analogue
Scale (VAS) in a random sample of the Canadian
general population, resulting in possible utility scores
ranging from -0.36 to 1.00 [59].
3. (Societal) costs, including resources consumed
within the health care sector, such as NICU admis-
sions, hospital admissions, diagnostics, treatments,
surgical interventions, and special needs (e.g. phy-
siotherapy, occupational therapy or speech therapy);
resources consumed outside the health care sector,
such as support, special education, school absence
and institutional care; patient and family costs, such
as out-of-pocket expenses, travel costs and time
costs; and productivity costs.
Data analysis
Empirical data
Health outcomes of the singleton and twin children,
including mortality, perinatal outcomes, morbidity and
developmental and behavioural problems will be ana-
lysed. Subsequently, health outcomes will be expressed
in QALYs. QALYs will be calculated based on mortality
and HRQoL data retrieved from both the EQ-5D and
the HUI. Costs will be calculated by multiplying
volumes of resource use with the cost price. Cost prices
will be obtained from the Dutch manual of costing stu-
dies [60] and financial departments of the participating
centres. For cost prices that are not readily available,
such as institutional care, special education and school
absence, cost price calculations will be performed.
Descriptive statistics will be used to describe the main
characteristics and outcomes of IVF singleton and twin
children. The base sample and the reduced sample are
not representative of the Dutch IVF population as a
consequence of the risk stratification and the random
selection of subsamples of healthy children. Therefore,
before analysing the data, the proportions of high, mod-
erate and low risk singletons and twin children will be
adjusted, to properly reflect the ratios in the original
population.
Results will be presented with and without stratifica-
tion for maternal age and parity. The issue of selection
(information) bias will be investigated explicitly by com-
paring PRN data of children with (completely) missing
data with PRN data of children included in the analysis.
Development TwinSing model
A prognostic model will be developed which estimates
the short and long-term costs and health outcomes of
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modelling method of the TwinSing model will be deter-
mined in close cooperation with experts in the project
team and the participating centres. We expect that a
Markov model will best suit the data; however, the final
decision regarding which modelling method to use will
be made after data become available.
Short and long-term cost-effectiveness of SET strategies
versus DET strategies
The TwinSing model will be linked to a short-term
Markov model developed at the University Hospital
Maastricht [32], that compared seven embryo transfer
strategies varying from three cycles SET to three cycles
DET and several combination strategies. Parameter
values were based on data from a large randomised con-
trolled trial in which patients who started their first IVF
cycle in the Maastricht University Medical Centre were
included.
The economic evaluation will be performed from both
the societal and the health care perspective and the time
horizon will be 18 years. Cost and benefits occurring
after one year will be discounted according to national
guidelines [61].
The ultimate model - in which the short-term Markov
model and the TwinSing model have been integrated -
will enable the estimation of the cost-effectiveness of
SET strategies versus DET strategies, expressed as the
additional costs per life year gained and the additional
costs per QALY. The cost-effectiveness will be analysed
using a short term time frame (1-year) and a long term
time frame (5 and 18-year).
Uncertainty in the model will be investigated by one-way
sensitivity analysis and probabilistic sensitivity analysis.
One-way sensitivity analysis will be used to test the
robustness of the results for (methodological) uncertainties
(e.g. discount rate and health-related quality of life instru-
ment used). Parameter uncertainty will be further tested
using probabilistic sensitivity analysis. Distributions will be
fitted for all parameters in the model, except fixed para-
meters. Beta distributions will be fitted for probabilities
and gamma distributions will be fitted for costs. Net
monetary benefits (NMB) will be calculated for each strat-
egy and cost-effectiveness acceptability curves (CEACs)
will be constructed. CEACs provide a graphical represen-
tation of the probability that a strategy is cost-effective for
a range of ceiling ratios. Subsequently, the cost-effective-
ness acceptability frontier (CEAF) will be established, to
indicate the preferred strategy.
As most parents prefer a complete family instead of
one child, a secondary analysis will be performed in
which the cumulative pregnancy rates and live birth
rates of subsequent IVF treatments (up to three) will be
estimated. Doing so, the costs and outcomes of children
of the second or third IVF treatment will be evaluated
to estimate the cost-effectiveness of SET strategies ver-
sus DET strategies.
Value of information analysis
Inherent to modelling is that results are surrounded by
an amount of uncertainty. Value of information analysis
addresses the issue whether the most efficient embryo
transfer strategy can be adopted based on the available
knowledge after finishing this study or whether more
evidence is required [62-65]. An expected value of per-
fect information (EVPI) analysis will be performed,
which draws on the probabilistic model developed in
this study. Subsequently partial EVPIs will be calculated
to identify the parameters for which more accurate esti-
mates are the most valuable and which should be the
focus of future research.
Ethical considerations
The study protocol has been reviewed and approved by
the Medical Ethical Committee of the Maastricht Uni-
versity Medical Centre (MUMC). Parents will be
informed in written format about the TwinSing study
and are asked to return a signed informed consent form
if they decide to participate in the parent questionnaire.
Funding
A grant was obtained from the efficiency research pro-
gramme, round 2009, of the Netherlands Organization
for Health and Development (ZonMW).
Discussion
Multiple pregnancies are regarded as a complication of
IVF. To date, SET is more and more accepted as the solu-
tion for the high frequency of twin pregnancies after IVF.
To support the claim that twin pregnancies are a compli-
cation of IVF, the long-term costs and outcomes of twins
and singletons should be determined. To our knowledge
this is the first study on both long-term (societal) costs
and health outcomes of IVF twins and singletons, allowing
us to calculate the long-term cost-effectiveness of several
(combinations of) SET and/or DET strategies.
This study will use QALYs as outcome measure,
which will enhance comparison with other health care
programs and the interpretation of the ICERs. Further-
more, this study will be conducted from the societal
perspective and this includes not only hospital costs, but
also productivity, patient and family costs. Most pre-
vious studies focused on hospital costs only, neglecting
costs outside the healthcare sector. Analyses will also be
performed from the healthcare perspective.
Another strength of this study protocol is its efficient
design. The larger part of the health problems and asso-
ciated costs will occur in a relatively small group of chil-
dren. The study is set up such that data collection
focuses on these children. Data collection regarding the
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health problems due to a prematurity, a low Apgar
score, a congenital malformation or a low birth weight.
Data collection regarding the second to fifth year of life
is focused on children who experienced health problems
during their first life year. Additional advantage is that,
due to the decreasing number of participants making up
the sample size in later stages of the study, a particularly
high level of detail can be reached in the data collection.
Although this study will apply the commonly used
QALY as measure of outcome, a number of potential
problems are to be expected. The first question is
whether the QALY concept is suitable to value QALYs
‘generated’ or ‘created’,i n s t e a do fQ A L Y sgained,f o r
which the QALY framework was originally developed.
Furthermore, a twin consists of two live-born children.
An interesting issue in using QALYs as outcome mea-
sure is that a healthy twin will theoretically generate
twice as much QALYs as a healthy singleton, which is
the total opposite compared to how twins have been
valued in cost-effectiveness analyses thus far. As twins
are more common among woman receiving DET,
including the QALYs of both twin children in the cost-
effectiveness analysis will have considerable impact on
the ICERs [32]. Furthermore, it can be expected that
parents with a single child after SET, will more often
undergo subsequent IVF treatment(s) than parents with
a twin after DET. As a result, the long-term cost-effec-
tiveness analysis including only the first IVF treatment
is of limited value. It does not reflect the real world
situation in which parents can opt for up to three IVF
treatments. Our secondary analysis including subsequent
IVF treatments will take account of this imbalance.
Moreover, when using QALYs, an interesting question
is furthermore whether the QALYs of parents and sib-
lings should be taken into account as well. For example,
the birth of a (handicapped) child may have a consider-
able impact on family members. It should be considered,
if and how QALYs of the parent and family members
should be included in the analysis.
Conclusion
This study will provide information on the short and
long-term incremental (societal costs) and health out-
comes of IVF twin children compared with IVF single-
tons. Subsequently, it will provide further evidence
regarding whether SET strategies are more efficient than
DET strategies. Results of this study will be of interest
for patients, clinicians, health care policymakers and
insurers, both nationally and internationally.
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